格隆汇8月21日丨安图生物(603658.SH)公布2025年半年度报告，报告期实现营业收入20.6亿元，同比下 降6.65%；归属于上市公司股东的净利润5.71亿元，同比下降7.83%；归属于上市公司股东的扣除非经常 性损益的净利润5.46亿元，同比下降8.79%；基本每股收益1.02元。 ...

安图生物公告，2025年上半年营业收入20.6亿元，同比下降6.65%。净利润5.71亿元，同比下降7.83%。 ...

Group 1 - The company reported a net profit of 571 million RMB for the first half of the year [1]

Core Viewpoint - Antu Biology's stock closed at 41.82 yuan, with a rolling PE ratio of 20.96 times, and a total market capitalization of 23.897 billion yuan, indicating a relatively lower valuation compared to the industry average [1] Company Summary - Antu Biology specializes in the research, manufacturing, integration, and service of in vitro diagnostic reagents and instruments, with key products including immunodiagnostic reagents, microbiological testing reagents, molecular diagnostic reagents, biochemical reagents, and instruments [1] - The company was listed among the "Top 100 Pharmaceutical Companies in China for 2023" and achieved second place in the "Top 100 Pharmaceutical Enterprises R&D Index" due to its outstanding performance in R&D results and support indices [1] Financial Performance - For the first quarter of 2025, Antu Biology reported a revenue of 996 million yuan, a year-on-year decrease of 8.56%, and a net profit of 270 million yuan, down 16.76% year-on-year, with a gross profit margin of 65.07% [1] - As of the first quarter of 2025, three institutions held shares in Antu Biology, with a total holding of 12.7156 million shares valued at 477 million yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 59.32 times, with a median of 39.97 times, positioning Antu Biology at 43rd place within the industry [1][2] - The industry average market capitalization is 121.09 billion yuan, with the median at 59.06 billion yuan, indicating that Antu Biology operates in a competitive market environment [2]

金融界消息 截至2025年8月19日收盘，安图生物（603658）报收于41.25元，下跌0.55%，换手率 0.63%，成交量3.59万手，成交金额1.49亿元。 天眼查商业履历信息显示，郑州安图生物工程股份有限公司，成立于1999年，位于郑州市，是一家以从 事医药制造业为主的企业。企业注册资本57142.4768万人民币，实缴资本37800万人民币。公司法定代 表人为杨增利。 通过天眼查大数据分析，郑州安图生物工程股份有限公司共对外投资了19家企业，参与招投标项目1200 次，知识产权方面有商标信息76条，专利信息598条，此外企业还拥有行政许可1559个。 来源：金融界 资金流向方面，今日主力资金净流出1239.47万元，占比成交额8.33%。其中，超大单净流出83.42万 元、占成交额0.56%，大单净流出1156.05万元、占成交额7.77%，中单净流出流入799.85万元、占成交 额5.37%，小单净流入439.62万元、占成交额2.95%。 安图生物最新一期业绩显示，截至2025一季报，公司营业总收入9.96亿元、同比减少8.56%，归属净利 润2.70亿元，同比减少16.76%，扣非净利润2. ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market activity of Antu Biology (安图生物), indicating a decline in revenue and net profit in the latest quarterly report [1] - As of August 13, 2025, Antu Biology's stock closed at 42.16 yuan, down 0.28%, with a trading volume of 42,600 lots and a transaction amount of 179 million yuan [1] - The company experienced a net outflow of main funds amounting to 10.72 million yuan, representing 5.98% of the transaction amount, with significant outflows from large orders [1] Group 2 - For the first quarter of 2025, Antu Biology reported total operating revenue of 996 million yuan, a year-on-year decrease of 8.56%, and a net profit attributable to shareholders of 270 million yuan, down 16.76% year-on-year [1] - The company has a current ratio of 2.625, a quick ratio of 2.149, and a debt-to-asset ratio of 25.05%, indicating a strong liquidity position [1] - Antu Biology has made investments in 19 companies and participated in 1,183 bidding projects, showcasing its active engagement in the market [2]

Group 1: Company Developments - Zhengzhou Coal Mining Machinery Group (Zhengmei) has successfully secured an order for high-end intelligent mining equipment to be exported to Indonesia, marking a significant achievement in the international market [1][2] - The equipment is designed for coal seam mining over 6 meters and is noted for its advanced level of automation, positioning Zhengmei as a leader in the industry [1] - The collaboration with Indonesia's TCM company represents a key project under China's Belt and Road Initiative, showcasing the global reach of Zhengmei's products [1] Group 2: Financial Support and Risk Management - China Export & Credit Insurance Corporation (Sinosure) provided crucial support to Zhengmei by conducting a rapid credit assessment of the Indonesian buyer, enabling the project to proceed despite potential financial risks [2] - Sinosure has been a long-term partner of Zhengmei since 2007, with total insured amounts exceeding $200 million, facilitating order acquisition and risk management for overseas projects [2] - In the first half of the year, Sinosure's overall insured amount reached $56.29 billion, reflecting an 18.7% year-on-year increase, indicating strong support for companies in the region [3] Group 3: Industry Growth and Export Performance - The foreign trade import and export volume of Henan Province reached 412.53 billion yuan in the first half of the year, a 26.2% increase year-on-year, highlighting the province's robust economic performance [3] - Sinosure's support has been instrumental in helping various manufacturing enterprises, including Zhengmei and AnTu Bioengineering, expand their international presence and manage risks effectively [10][12] - The collaboration between Sinosure and local companies has led to significant growth in exports, with AnTu Bioengineering's overseas sales projected to exceed 284 million yuan in 2024, a 36.25% increase from 2023 [4][5] Group 4: Cross-Border E-commerce and Innovation - Zhengzhou has emerged as a hub for cross-border e-commerce, with companies like Zhiou Home Technology leveraging innovative logistics and risk management solutions to expand their international market reach [11][12] - Sinosure has tailored risk management services for cross-border e-commerce businesses, resulting in a 284.6% increase in insured amounts for this sector in the first half of the year [12] - The establishment of a provincial-level political risk insurance platform for cross-border e-commerce aims to enhance the support system for foreign trade enterprises, fostering innovation and growth in the sector [12][13]

Core Insights - Antu Biology (603658) reported a closing price of 42.28 yuan as of August 12, 2025, with a slight decline of 0.14% [1] - The company experienced a total revenue of 996 million yuan in Q1 2025, representing a year-on-year decrease of 8.56% [1] - Net profit attributable to shareholders was 270 million yuan, down 16.76% year-on-year [1] Financial Performance - Total revenue for Q1 2025: 996 million yuan, down 8.56% year-on-year [1] - Net profit: 270 million yuan, down 16.76% year-on-year [1] - Non-recurring net profit: 257 million yuan, down 18.19% year-on-year [1] - Current ratio: 2.625 [1] - Quick ratio: 2.149 [1] - Debt-to-asset ratio: 25.05% [1] Market Activity - The stock had a turnover rate of 0.86% with a trading volume of 49,100 lots and a transaction amount of 207 million yuan [1] - Net inflow of main funds was 12.63 million yuan, accounting for 6.09% of the transaction amount [1] - Large orders saw a net inflow of 15.30 million yuan, while small orders had a net outflow of 11.99 million yuan [1] Company Background - Antu Biology was established in 1999 and is located in Zhengzhou, primarily engaged in the pharmaceutical manufacturing industry [2] - The company has a registered capital of 5.71424768 billion yuan and a paid-in capital of 378 million yuan [1][2] - The legal representative of the company is Yang Zengli [1] Investment and Intellectual Property - Antu Biology has invested in 19 enterprises and participated in 1,182 bidding projects [2] - The company holds 83 trademark registrations and 598 patent registrations [2] - Additionally, it possesses 1,558 administrative licenses [2]

Core Viewpoint - Antu Biology's stock closed at 42.34 yuan, up 3.39%, with a rolling PE ratio of 21.22, marking a new low in 88 days, and a total market capitalization of 24.194 billion yuan [1] Company Summary - Antu Biology specializes in the research, manufacturing, integration, and service of in vitro diagnostic reagents and instruments, with key products including immunodiagnostic reagents, microbiological testing reagents, molecular diagnostic reagents, biochemical reagents, and instruments [1] - As of March 31, 2025, the number of shareholders reached 34,163, an increase of 3,382 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The latest quarterly report for Q1 2025 shows revenue of 996 million yuan, a year-on-year decrease of 8.56%, and a net profit of 270 million yuan, down 16.76%, with a gross profit margin of 65.07% [1] Industry Summary - The average PE ratio for the medical device industry is 56.56, with a median of 39.76, placing Antu Biology at 45th in the industry ranking [1] - The industry average market capitalization is 118.97 billion yuan, while the median is 57.67 billion yuan [2]

来源：金融界 主力资金净流出居前的分别为安杰思（1536.17万元）、科华生物（1457.06万元）、海利生物（1440.72 万元）、华大基因（1419.47万元）、福瑞股份（1329.15万元）。 序号代码名称最新价涨跌幅主力净流入主力净占比1300760迈瑞医疗230.5-0.098724.29万元 6.07%2300753爱朋医疗34.261.935531.45万元7.53%3300314戴维医疗15.2510.035504.85万元 11.77%4603658安图生物42.343.394457.47万元15.08%5688273麦澜德44.759.234025.59万元9.14%6002432 九安医疗40.121.192866.50万元6.27%7600587新华医疗18.144.432682.44万元3.88%8300453三鑫医疗 9.413.982472.80万元10.27%9688271联影医疗130.68-0.021943.47万元5.25%10603309维力医疗 14.92.831756.01万元10.29% 8月11日，医疗器械行业上涨1.65%，今日主力资金流出4.97亿元，成分 ...